Dr. John Harrison is Honorary Senior Lecturer in the Dept. of Medicine at Imperial College London and Principal Consultant at Metis Cognition Ltd. Metis is an applied psychology practice established to advise pharmaceutical companies with the selection and successful integration of cognitive testing into their development programs. Metis provide consultancy to more than 40 companies involved in the development of new drugs for indications including Alzheimer’s disease, depression, schizophrenia and Parkinson’s disease. Recent successes include:
- *Assistance with outcome selection in the successful Souvenaid program for Nutricia
- *Development of the novel Cognitive Composite measure used to show positive effects of Envivo’s EVP6124 compound in a phase 2 Alzheimer’s study
- *Assistance to Lundbeck with the successful development of their Brintellix anti-depressant compound
John has previously served as Head of Neuropsychology at CeNeS Pharmaceuticals (1997-2000), Principal Consultant of CPC Pharma Services (2000-2007) and as Principal Scientist at CogState Ltd. (2007-2011). He speaks on the use of cognitive testing at various international meetings, including the American Alzheimer’s Association roundtable events, the European Task Force for Alzheimer’s disease and the THINC Cognition in Depression initiative. Last year he hosted the Games for Health Europe meeting and has maintained a keen interest in the potential for applied gaming since participating in the creation of ‘EVE’ with Peter Gabriel in 1996. He is a member of the American Psychological Association, holds Chartered Psychologist status with the British Psychological Society, and Chartered Scientist status with the Science Council. He has authored/co-authored more than 50 books and scientific articles, including a popular neuroscience book ‘Synaesthesia: The Strangest Thing’.